Magnesium Sulfate in combination with Nifedipine in the treatment of Pregnancy-Induced Hypertension

OBJECTIVE: To investigate the effect of magnesium sulfate combined with nifedipine in the treatment of pregnancy-induced hypertension syndrome (PIHS). METHODS: Total 118 pregnant women with PIHS who were admitted to our hospital from April 2017 to June 2018 were randomly divided into control group (59 cases) and observation group (59 cases). The observation group was treated by magnesium sulfate in combination with nifedipine, while the control group was treated by magnesium sulfate. The therapeutic effect, serum leukaemia inhibitory factor (LIF), Apelin level, blood pressure, blood viscosity, urinary protein, S/D and Umbilical Artery Resistance Index (UARI) were compared between the two groups. RESULTS: The effective rate of the observation group was 94.9%, higher than 83.1% of the control group, and the difference was statistically significant (P<0.05). The decrease level of systolic and diastolic blood pressure in the observation group was better than that in the control group, and the difference was statistically significant (P<0.05). The decrease of blood viscosity, urinary protein, S/D and UARI in the observation group was greater than that in the control group, and the difference was statistically significant (P<0.05). The improvement of serum LIF and Apelin levels in the observation group was better than that in the control group (P<0.05), and the difference was statistically significant (P<0.05). CONCLUSION: Magnesium sulfate combined with nifedipine in the treatment of PIHS has a significant effect, which can effectively control edema, blood pressure, proteinuria and protect kidney. It is worth clinical promotion.